Chronic Lymphocytic Leukemia
Juno Therapeutics, Inc, has filed a registration statement for an initial public offering of its common stock, as its early stage therapies continue to advance in clinical trials.
Most Popular Right Now
Gary M. Kirsh, MD, Earl L. Walz, and Pamela Skurkay discuss the integration of the autologous cellular immunotherapy sipuleucel-T (Provenge) into clinical practice for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. View Now